Skip to main content
. 2021 May 14;67:103380. doi: 10.1016/j.ebiom.2021.103380

Table 1.

Demographics.

PD Subjectsa
N Mean (SD)
Age (years) 5 64 (5)
Time Since Diagnosis (years) 5 8 (5)
UPDRS Part III Score 5 20 (5)
N Percentage
Male Sex 5 100
Caucasian Race 5 100
Anti-Parkinsonian Therapy:
Carbidopa-Levodopa 25-100 mgb 3 60
Carbidopa-Levodopa 50-200 mg 1 20
Carbidopa-Levodopa 23-95 mg 1 20
a

Demographic data taken from subjects at the time of enrollment

b

Subject 2001 began anti-parkinsonian therapy on month 8